Warfarin Pharmacogenetics: Ready for Clinical Utility?(Clinical PRACTICE) Warfarin Pharmacogenetics: Ready for Clinical Utility?(Clinical PRACTICE)

Warfarin Pharmacogenetics: Ready for Clinical Utility?(Clinical PRACTICE‪)‬

Clinical Laboratory Science 2009, Summer, 22, 3

    • $5.99
    • $5.99

Publisher Description

Despite the Federal Drug Administration's August 2007 relabeling of warfarin to recommend pharmacogenetic (PGx) testing, the clinical application remains controversial. Many questions exist regarding how information gleaned from genetic testing can be applied in warfarin therapy. In particular, does PGx testing lead to a shorter time to stable INR compared to prudent international normalized ratio (INR) monitoring coupled with the consideration of age, BMI, diet, and physical condition? Does it reduce clinical complications? Other topics of uncertainty include whether the correct warfarin dose can be obtained based on genotype, whether PGx testing is cost-effective, and turn-around-time. Despite the reservations about warfarin PGx testing, there are several subsets of patients for whom such testing could be beneficial. BACKGROUND

GENRE
Professional & Technical
RELEASED
2009
June 22
LANGUAGE
EN
English
LENGTH
13
Pages
PUBLISHER
American Society for Clinical Laboratory Science
SELLER
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
176.8
KB

More Books Like This

Principles of Pharmacogenetics and Pharmacogenomics Principles of Pharmacogenetics and Pharmacogenomics
2012
Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring Resolving Erroneous Reports in Toxicology and Therapeutic Drug Monitoring
2012
Handbook of Drug-Nutrient Interactions Handbook of Drug-Nutrient Interactions
2011
Efficacy of Pravastatin in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and Protease Inhibitor (Pi)-Based HAART in Hiv-Infected Patients (Highly Active Antiretroviral Therapy) (Report) Efficacy of Pravastatin in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) and Protease Inhibitor (Pi)-Based HAART in Hiv-Infected Patients (Highly Active Antiretroviral Therapy) (Report)
2008
Prospective Investigations of Concentration--Clinical Response for Immunosuppressive Drugs Provide the Scientific Basis for Therapeutic Drug Monitoring (Tdm Conference) (Clinical Report) Prospective Investigations of Concentration--Clinical Response for Immunosuppressive Drugs Provide the Scientific Basis for Therapeutic Drug Monitoring (Tdm Conference) (Clinical Report)
1998
Biotin and Other Interferences in Immunoassays Biotin and Other Interferences in Immunoassays
2019

More Books by Clinical Laboratory Science

Just Culture-Changing the Environment of Healthcare Delivery (Focus: PATIENT SAFETY AND THE MEDICAL Laboratory) (Report) Just Culture-Changing the Environment of Healthcare Delivery (Focus: PATIENT SAFETY AND THE MEDICAL Laboratory) (Report)
2011
CLS Entry Level Competencies in Flow Cytometry (Research AND Reports) (Clinical Laboratory Scientists ) (Report) CLS Entry Level Competencies in Flow Cytometry (Research AND Reports) (Clinical Laboratory Scientists ) (Report)
2011
Career Research Opportunities for the Medical Laboratory Scientist (Clinical Practice) (Report) Career Research Opportunities for the Medical Laboratory Scientist (Clinical Practice) (Report)
2011
Teaching Method Validation in the Clinical Laboratory Science Curriculum (Clinical PRACTICE) Teaching Method Validation in the Clinical Laboratory Science Curriculum (Clinical PRACTICE)
2008
Factor V Leiden: An Overview (Clinical PRACTICE) Factor V Leiden: An Overview (Clinical PRACTICE)
2006
Molecular Bacteriology in the Clinical Laboratory (Focus: MOLECULAR METHODS IN CLINICAL MICROBIOLOGY) Molecular Bacteriology in the Clinical Laboratory (Focus: MOLECULAR METHODS IN CLINICAL MICROBIOLOGY)
2010